Morphine-induced nitric oxide production in PC12 cells

Archives of Iranian Medicine

Volumn 15, Issue 7, 2012, Pages 404-408

  Zarrindast, Mohammad Reza ^a,b,c,d   Javadi Paydar, Mehrak ^e   Delphi, Ladan ^f   Vousooghi, Nasim ^b,g  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c INSTITUTE FOR STUDIES IN THEORETICAL PHYSICS AND MATHEMATICS IPM   (Iran)

^d INSTITUTE FOR COGNITIVE SCIENCE STUDIES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f UNIVERSITY OF TEHRAN   (Iran)

^g TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Morphine; Nitric oxide; NMDA; PC12 cells

Indexed keywords

LIPOPOLYSACCHARIDE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALOXONE; NITRIC OXIDE;

ACUTE DRUG ADMINISTRATION; ANIMAL CELL; ARTICLE; CELL STRAIN; CHRONIC DRUG ADMINISTRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; INCUBATION TIME; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RAT;

ANALGESICS, OPIOID; ANIMALS; LIPOPOLYSACCHARIDES; MORPHINE; N-METHYLASPARTATE; NITRIC OXIDE; PC12 CELLS; RATS;

EID: 84865633513     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991; 43: 109-142.
2. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature. 1990; 347: 768-770.
3. Yun HY, Dawson VL, Dawson TM. Neurobiology of nitric oxide. Crit Rev Neurobiol. 1996; 10: 291-316.
4. Kumar S, Bhargava HN. Time course of the changes in central nitric oxide synthase activity following chronic treatment with morphine in the mouse: reversal by naltrexone. Gen Pharmacol. 1997; 29: 223-227.
5. Toda N, Kishioka S, Hatano Y, Toda H. Interactions between morphine and nitric oxide in various organs. J Anesth. 2009; 23: 554-568.
6. Minneman KP, Iversen IL. Enkephalin and opiate narcotics increase cyclic GMP accumulation in slices of rat neostriatum. Nature. 1976; 262: 313-314.
7. Duarte ID, Ferreira SH. The molecular mechanism of central analgesia induced by morphine or carbachol and the L-arginine-nitric oxidecGMP pathway. Eur J Pharmacol. 1992; 221: 171-174.
8. Pataki I, Telegdy G. Further evidence that nitric oxide modifies acute and chronic morphine actions in mice. Eur J Pharmacol. 1998; 357: 157-162.
9. Kolesnikov YA, Pick CG, Pasternak GW. NG-nitro-L-arginine prevents morphine tolerance. Eur J Pharmacol. 1992; 221: 399-400.
10. Kivastik T, Rutkauskaite J, Zharkovsky A. Nitric oxide synthesis inhibition attenuates morphine-induced place preference. Pharmacol Biochem Behav. 1996; 53: 1013-1015.
11. Sucher NJ, Awobuluyi M, Choi YB, Lipton SA. NMDA receptors: from genes to channels. Trends Pharmacol Sci. 1996; 17: 348-355.
12. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988; 1: 623-634.
13. Devulder JE. Could nitric oxide be an important mediator in opioid tolerance and morphine side effects? J ClinAnesth. 2002; 14: 81-82.
14. Gracy KN, Pickel VM. Ultrastructural localization and comparative distribution of nitric oxide synthase and N-methyl-D-aspartate receptors in the shell of the rat nucleus accumbens. Brain Res. 1997; 747: 259-272.
15. Gonzalez P, Cabello P, Germany A, Norris B, Contreras E. Decrease of tolerance to, and physical dependence on morphine by, glutamate receptor antagonists. Eur J Pharmacol. 1997; 332: 257-262.
16. Lutfy K, Hurlbut DE, Weber E. Blockade of morphine-induced analgesia and tolerance in mice by MK-801. Brain Res. 1993; 616: 83-88.
17. Bristow LJ, Hogg JE, Hutson PH. Competitive and glycine/NMDA receptor antagonists attenuate withdrawal-induced behaviours and increased hippocampal acetylcholine effiux in morphine-dependent rats. Neuropharmacology. 1997; 36: 241-250.
18. Ribeiro D, Couto B, Aguilar MA, Manzanedo C, Rodriguez-Arias M, Minarro J. Effects of NMDA receptor antagonists (MK-801 and memantine) on the acquisition of morphine-induced conditioned place preference in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28: 1035-1043.
19. Nakagawa T, Minami M, Satoh M. Up-regulation of RGS4 mRNA by opioid receptor agonists in PC12 cells expressing cloned mu-or kappaopioid receptors. Eur J Pharmacol. 2001; 433: 29-36.
20. Taupenot L. Analysis of regulated secretion using PC12cells. Curr Protoc Cell Biol.2007; Chapter 15:Unit 15.12
21. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol. 1988; 141: 2407-2412.
22. Xie QW, Cho HJ, Calaycay J, Mumford RA, Swiderek KM, Lee TD, et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science.1992; 256: 225-228.
23. Seyffarth G, Nelson PN, Dunmore SJ, Rodrigo N, Murphy DJ, Carson RJ. Lipopolysaccharide induces nitric oxide synthase expression and platelet-activating factor increases nitric oxide production in human fetal membranes in culture. Reprod Biol Endocrinol. 2004; 2: 29.
24. Mustafa SB, Olson MS. Expression of nitric-oxide synthase in rat Kupffer cells is regulated by cAMP. J Biol Chem. 1998; 273: 5073-5080.
25. Iuvone T, Capasso A, D'Acquisto F, Carnuccio R. Opioids inhibit the induction of nitric oxide synthase in J774 macrophages. Biochem Biophys Res Commun. 1995; 212: 975-980.
26. Singhal PC, Sharma P, Kapasi AA, Reddy K, Franki N, Gibbons N. Morphine enhances macrophage apoptosis. J Immunol. 1998; 160: 1886-1893.
27. Martucci C, Franchi S, Lattuada D, Panerai AE, Sacerdote P. Differential involvement of Rel B in morphine-induced modulation of chemotaxis, NO, and cytokine production in murine macrophages and lymphocytes. J Leukoc Biol. 2007; 81: 344-354.
28. Saurer TB, Ijames SG, Lysle DT. Evidence for the nucleus accumbens as a neural substrate of heroin-induced immune alterations. J Pharmacol Exp Ther. 2009; 329: 1040-1047.
29. Bhargava HN. Attenuation of tolerance to, and physical dependence on, morphine in the rat by inhibition of nitric oxide synthase. Gen Pharmacol. 1995; 26: 1049-1053.
30. Cuellar B, Fernandez AP, Lizasoain I, Moro MA, Lorenzo P, Bentura ML, et al. Up-regulation of neuronal NO synthase immunoreactivity in opiate dependence and withdrawal. Psychopharmacology (Berl). 2000; 148: 66-73.
31. Nieto-Fernandez FE, Mattocks D, Cavani F, Salzet M, Stefano GB. Morphine coupling to invertebrate immunocyte nitric oxide release is dependent on intracellular calcium transients. Comp BiochemPhysiol B Biochem Mol Biol. 1999; 123: 295-299.
32. Lanier RK, Ijames SG, Carrigan KA, Carelli RM, Lysle DT. Self-administration of heroin produces alterations in the expression of inducible nitric oxide synthase. Drug Alcohol Depend. 2002; 66: 225-233.
33. Lysle DT, Carrigan KA. Morphine-6beta-glucuronide modulates the expression of inducible nitric oxide synthase. Inflammation. 2001; 25: 267-275.
34. Barjavel MJ, Bhargava HN. Effect of opioid receptor agonists on nitric oxide synthase activity in rat cerebral cortex homogenate. Neurosci-Lett. 1994; 181: 27-30.
35. Leza JC, Lizasoain I, San-Martin-Clark O, Lorenzo P. Morphine-induced changes in cerebral and cerebellar nitric oxide synthase activity. Eur J Pharmacol. 1995; 285: 95-98.
36. Mastronicola D, Arcuri E, Arese M, Bacchi A, Mercadante S, Cardelli P, et al. Morphine but not fentanyl and methadone affects mitochondrial membrane potential by inducing nitric oxide release in glioma cells. Cell Mol Life Sci. 2004; 61: 2991-2997.
37. Yoshikawa M, Nakayama H, Ueno S, Hirano M, Hatanaka H, Furuya H. Chronic fentanyl treatments induce the up-regulation of mu opioid receptor mRNA in rat pheochromocytoma cells. Brain Res. 2000; 859: 217-223.
38. Abood ME, Tao Q. Characterization of a delta opioid receptor in rat pheochromocytoma cells. J Pharmacol Exp Ther. 1995; 274: 1566-1573.
39. Margioris AN, Venihaki M, Stournaras C, Gravanis A. PC12 cells as a model to study the effects of opioids on normal and tumoral adrenal chromaffin cells. Ann N Y Acad Sci. 1995; 771: 166-172.
40. Goumon Y, Zhu W, Weeks BS, Casares F, Cadet P, Bougaeva M, et al. Identification of morphine in the adrenal medullary chromaffin PC-12 cell line. Brain Res Mol Brain Res. 2000; 81: 177-180.
41. Albensi BC. The NMDA receptor/ion channel complex: a drug target for modulating synaptic plasticity and excitotoxicity. Curr Pharm Des. 2007; 13: 3185-3194.
42. Le DA, Lipton SA. Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging. Drugs Aging. 2001; 18: 717-724.
43. Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem. 1994; 63: 175-195.
44. Edwards MA, Loxley RA, Williams AJ, Connor M, Phillips JK. Lack of functional expression of NMDA receptors in PC12 cells. Neurotoxicology. 2007; 28: 876-885.
45. Schubert D, Kimura H, Maher P. Growth factors and vitamin E modify neuronal glutamate toxicity. Proc Natl Acad Sci U S A. 1992; 89: 8264-8267.
46. Vazhappilly R, Sucher NJ. Translational regulation of the N-methyl-D-aspartate receptor subunit NR1. Neurosignals. 2004; 13: 190-193.
47. Vazhappilly R, Sucher NJ. Turnover analysis of N-methyl-D-aspartate receptor subunit NR1 protein in PC12 cells. Neuro sci Lett. 2002; 318: 153-157.
48. Bajo M, Crawford EF, Roberto M, Madamba SG, Siggins GR. Chronic morphine treatment alters expression of N-methyl-D-aspartate receptor subunits in the extended amygdala. J Neurosci Res. 2006; 83: 532-537.